2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenHope the week will be good. And that everyone with negative statements has gone on holiday.
·1 päivä sittenSoftOx – Could this be the turning point? 🧪🚀 I think SoftOx is one of the most exciting biotech companies on the Oslo Stock Exchange right now. The risk is high, but the potential is also significant if they deliver on the next milestones. These are the triggers I'm following most closely: 🧬 Clinical studies The upcoming results from the clinical studies will be absolutely crucial. Positive safety and efficacy data can significantly reduce the risk in the case and increase market interest. 🤝 Partnerships and licensing agreements I believe many underestimate the value of an agreement with a larger pharmaceutical company. Such a collaboration can provide both capital, professional expertise, and a clear confirmation of the technology. 🌍 Large international market If SoftOx succeeds in developing treatments in areas with great medical need, the market potential is global. It's not just Norway they are targeting. 💰 Financing A stronger capital base or support from industrial partners could give the company peace of mind to develop projects further without constant focus on new financing. 📈 Growing interest in biotech When companies move from promising research to solid clinical data, valuation can change rapidly. We have seen many examples of this before. 👨⚕️ The road ahead The next few months will be important. Each positive milestone can help build confidence in the technology and the company's strategy. SoftOx is still a high-risk company. Clinical studies can yield both positive and negative surprises, and there are no guarantees. But precisely for this reason, I believe the upside can be significant if they deliver. I am a long-term holder and look forward to following the development further. It will be exciting to see what the rest of the year brings. Not investment advice – just my own thoughts as a shareholder. 🧪📈💙
·2 päivää sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.
So you have invested in something super secret like (vinegar), that's really great!
·2 päivää sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.
can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀- ·2 päivää sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenHope the week will be good. And that everyone with negative statements has gone on holiday.
- ·1 päivä sittenSoftOx – Could this be the turning point? 🧪🚀 I think SoftOx is one of the most exciting biotech companies on the Oslo Stock Exchange right now. The risk is high, but the potential is also significant if they deliver on the next milestones. These are the triggers I'm following most closely: 🧬 Clinical studies The upcoming results from the clinical studies will be absolutely crucial. Positive safety and efficacy data can significantly reduce the risk in the case and increase market interest. 🤝 Partnerships and licensing agreements I believe many underestimate the value of an agreement with a larger pharmaceutical company. Such a collaboration can provide both capital, professional expertise, and a clear confirmation of the technology. 🌍 Large international market If SoftOx succeeds in developing treatments in areas with great medical need, the market potential is global. It's not just Norway they are targeting. 💰 Financing A stronger capital base or support from industrial partners could give the company peace of mind to develop projects further without constant focus on new financing. 📈 Growing interest in biotech When companies move from promising research to solid clinical data, valuation can change rapidly. We have seen many examples of this before. 👨⚕️ The road ahead The next few months will be important. Each positive milestone can help build confidence in the technology and the company's strategy. SoftOx is still a high-risk company. Clinical studies can yield both positive and negative surprises, and there are no guarantees. But precisely for this reason, I believe the upside can be significant if they deliver. I am a long-term holder and look forward to following the development further. It will be exciting to see what the rest of the year brings. Not investment advice – just my own thoughts as a shareholder. 🧪📈💙
- ·2 päivää sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.So you have invested in something super secret like (vinegar), that's really great!
- ·2 päivää sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀
- ·2 päivää sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
2026 Q1 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenHope the week will be good. And that everyone with negative statements has gone on holiday.
- ·1 päivä sittenSoftOx – Could this be the turning point? 🧪🚀 I think SoftOx is one of the most exciting biotech companies on the Oslo Stock Exchange right now. The risk is high, but the potential is also significant if they deliver on the next milestones. These are the triggers I'm following most closely: 🧬 Clinical studies The upcoming results from the clinical studies will be absolutely crucial. Positive safety and efficacy data can significantly reduce the risk in the case and increase market interest. 🤝 Partnerships and licensing agreements I believe many underestimate the value of an agreement with a larger pharmaceutical company. Such a collaboration can provide both capital, professional expertise, and a clear confirmation of the technology. 🌍 Large international market If SoftOx succeeds in developing treatments in areas with great medical need, the market potential is global. It's not just Norway they are targeting. 💰 Financing A stronger capital base or support from industrial partners could give the company peace of mind to develop projects further without constant focus on new financing. 📈 Growing interest in biotech When companies move from promising research to solid clinical data, valuation can change rapidly. We have seen many examples of this before. 👨⚕️ The road ahead The next few months will be important. Each positive milestone can help build confidence in the technology and the company's strategy. SoftOx is still a high-risk company. Clinical studies can yield both positive and negative surprises, and there are no guarantees. But precisely for this reason, I believe the upside can be significant if they deliver. I am a long-term holder and look forward to following the development further. It will be exciting to see what the rest of the year brings. Not investment advice – just my own thoughts as a shareholder. 🧪📈💙
- ·2 päivää sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.So you have invested in something super secret like (vinegar), that's really great!
- ·2 päivää sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀
- ·2 päivää sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt